Fujitsu Limited has introduced that its complete site visitors simulation system shall be built-in into the Maebashi City Regional Public Transportation Plan. The system, developed below the Ministry of Land, Infrastructure, Transport and Tourism’s COMmmmONS mission, gives scientific proof to assist the plan’s key measure of accelerating bus routes.

Addressing the wants of transportation-disadvantaged residents and the push for carbon neutrality are urgent points in Japan. Maebashi City faces challenges like demographic shifts, numerous mobility wants, and a scarcity of bus drivers, prompting the necessity for data-backed transportation options.

Fujitsu’s system, a primary in Japan, simulates each fixed-route and demand-responsive transportation. It makes use of social digital twin know-how to simulate human and social habits, leveraging statistical knowledge and ridership info from MaaS apps to guage coverage impacts precisely.

The system’s capabilities embrace high-precision simulations that generate resident journey knowledge, reflecting native traits. It employs AI to research journey modes and multi-agent simulation know-how to estimate journey demand, even with restricted precise journey knowledge.

By streamlining plan formulation, the system reduces the time required for consensus constructing with stakeholders by about 25%, a course of that beforehand took as much as two years. It presents complete analysis indicators for transportation insurance policies, aiding within the growth of sustainable regional transportation plans.

Fujitsu plans to commercialize the system by fiscal yr 2026, aiming to make it an ordinary software throughout Japan. The firm seeks to collaborate with native governments, consulting companies, and transportation operators to reinforce regional transportation planning.

Through these efforts, Fujitsu goals to assist city growth and neighborhood planning nationwide, contributing to the creation of sustainable cities. The COMmmmONS mission seeks to standardize greatest practices for regional transportation DX, specializing in collaboration and interoperability of digital providers and knowledge.

Hitachi, Ltd. (TSE:6501) has been acknowledged with the 2026 Catalyst Award for its dedication to embedding inclusion as a core part of its international administration and enterprise methods. The award, offered by Catalyst, a nonprofit group centered on office inclusion, acknowledges Hitachi’s efforts in fostering a extra inclusive company tradition.

The firm’s “Together, We Are Stronger” initiative has been instrumental in selling inclusive management and enhancing expertise practices. This initiative addresses long-standing cultural norms in Japan and is supported by senior management. Hitachi’s technique combines international governance with native implementation, aiming to speed up expertise alternatives throughout its numerous markets.

Key components of the initiative embody management improvement packages at numerous profession levels, clear expertise processes, and company-wide well-being efforts. These efforts are designed to advertise a tradition of psychological security, belief, and shared accountability, demonstrating how inclusion can improve organizational efficiency and innovation.

Lorena Dellagiovanna, Senior Vice President and Executive Officer, CHRO, and Chief Sustainability Officer at Hitachi, emphasised the significance of inclusion in constructing sturdy groups and fostering innovation. She acknowledged that the Catalyst Award affirms Hitachi’s journey and dedication to continued progress in office inclusion.

For extra data on Hitachi’s inclusion initiative, events can confer with the Hitachi Sustainability Report 2025.

Eisai Co., Ltd. and Biogen Inc. have introduced promising real-world findings on the long-term therapy persistence of their Alzheimer’s drug, lecanemab. The evaluation, introduced on the twentieth International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, revealed that almost all sufferers proceed therapy past the preliminary 18 months.

The examine, using the PurpleLab CLEAR Claims database, assessed 10,763 people within the U.S. who obtained intravenous lecanemab between January 2023 and November 2025. The findings confirmed that 78.4% of sufferers remained on therapy at 18 months, with persistence charges of 71.7% at 20 months and 67.3% at 24 months.

These outcomes align with the Phase III Clarity AD examine, the place 94% of sufferers opted to proceed with a long-term extension examine after finishing 18 months of therapy. The evaluation means that potential delays as a consequence of MRI monitoring and different elements didn’t considerably influence dosing adherence.

Lecanemab, developed by a collaboration between Eisai and BioArctic, targets amyloid-beta protofibrils, believed to contribute to Alzheimer’s development. The drug has been authorized in 53 nations, with upkeep dosing sanctioned in seven nations, together with the U.S. and China.

In scientific trials, lecanemab demonstrated a notable discount in cognitive decline, with a 1.01-point lower on the Clinical Dementia Rating-Sum of Boxes scale over three years, in comparison with the Alzheimer’s Disease Neuroimaging Initiative cohort. This profit elevated to a 1.75-point discount after 4 years.

The ongoing Phase 3 AHEAD 3-45 examine and the Tau NexGen scientific examine proceed to discover lecanemab’s potential in preclinical and dominantly inherited Alzheimer’s illness, respectively.

AEM Holdings Ltd., a frontrunner in check innovation, has introduced a strategic partnership with ASE Technology Holding Co., Ltd., the main supplier of semiconductor meeting, testing, and supplies companies. This collaboration goals to ship disruptive check options for the quickly increasing synthetic intelligence (AI) and high-performance computing (HPC) markets.

As a part of the partnership, AEM will elevate roughly S$12 million by way of a personal placement of three,350,000 strange shares to an entirely owned subsidiary of ASE. This represents 1.06% of AEM’s issued share capital as of March 21, 2026. ASE can even obtain 28,111,856 free removable warrants, divided into two exercisable tranches, contingent upon sure revenue-related situations. If totally exercised, the warrants might end in an extra 8.935% of the present issued share capital.

The funds from this personal placement will help AEM’s growth in Taiwan and the mixing of its check applied sciences into ASE’s manufacturing environments. This consists of extremely parallel check architectures and superior thermal administration capabilities. The proceeds can even advance AEM’s product roadmap and speed up joint go-to-market initiatives for next-generation AI and HPC functions.

The strategic partnership can even help ISE Labs, a subsidiary of ASE, in increasing its AI and HPC processor growth capabilities. This consists of addressing early-stage testing, validation, and characterization necessities with a give attention to heterogeneous integration architectures and optical interconnect applied sciences.

Ken Hsiang, CEO of ISE Labs, emphasised the significance of check as a vital enabler for efficiency, reliability, and manufacturability in next-generation AI and HPC programs. He famous that the partnership with AEM would facilitate a speedy transition from validation to high-volume deployment.

Samer Kabbani, CEO of AEM, highlighted the importance of the partnership in advancing AI and HPC testing. He praised ASE’s forward-looking strategy and international scale, which align with AEM’s technique to develop next-generation check options that improve efficiency, scalability, and time-to-market.

The transaction is topic to sure situations, together with the approval of the Singapore Exchange for the itemizing and citation of the brand new shares. Both firms are poised to leverage their strengths to fulfill the rising complexity and demand within the semiconductor trade.